These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 15634020

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Sauvagine analogs selective for corticotropin releasing factor 2 receptor: effect of substitutions at positions 35 and 39 on CRF2R selectivity.
    Mazur AW, Wang F, Tscheiner M, Donnelly E, Isfort RJ.
    Peptides; 2005 May; 26(5):887-91. PubMed ID: 15808919
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effects of a CRF2R agonist and exercise on mdx and wildtype skeletal muscle.
    Hall JE, Kaczor JJ, Hettinga BP, Isfort RJ, Tarnopolsky MA.
    Muscle Nerve; 2007 Sep; 36(3):336-41. PubMed ID: 17503504
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Urocortin II treatment reduces skeletal muscle mass and function loss during atrophy and increases nonatrophying skeletal muscle mass and function.
    Hinkle RT, Donnelly E, Cody DB, Bauer MB, Isfort RJ.
    Endocrinology; 2003 Nov; 144(11):4939-46. PubMed ID: 12960070
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Corticotropin-releasing factor 2 receptor localization in skeletal muscle.
    Samuelsson S, Lange JS, Hinkle RT, Tarnopolsky M, Isfort RJ.
    J Histochem Cytochem; 2004 Jul; 52(7):967-77. PubMed ID: 15208363
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Differential activation of CRF receptor subtypes removes stress-induced memory deficit and anxiety.
    Todorovic C, Radulovic J, Jahn O, Radulovic M, Sherrin T, Hippel C, Spiess J.
    Eur J Neurosci; 2007 Jun; 25(11):3385-97. PubMed ID: 17553007
    [Abstract] [Full Text] [Related]

  • 15. Peripheral injection of sauvagine prevents repeated colorectal distension-induced visceral pain in female rats.
    Million M, Maillot C, Adelson DA, Nozu T, Gauthier A, Rivier J, Chrousos GP, Bayati A, Mattsson H, Taché Y.
    Peptides; 2005 Jul; 26(7):1188-95. PubMed ID: 15949637
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Treatment with a corticotrophin releasing factor 2 receptor agonist modulates skeletal muscle mass and force production in aged and chronically ill animals.
    Hinkle RT, Lefever FR, Dolan ET, Reichart DL, Zwolshen JM, Oneill TP, Maloney KG, Mattson JP, Ferreira LF, Musch TI, Poole DC, Isfort RJ.
    BMC Musculoskelet Disord; 2011 Jan 14; 12():15. PubMed ID: 21235761
    [Abstract] [Full Text] [Related]

  • 20. The role of CRF receptors in anxiety and depression: implications of the novel CRF1 agonist cortagine.
    Todorovic C, Jahn O, Tezval H, Hippel C, Spiess J.
    Neurosci Biobehav Rev; 2005 Jan 14; 29(8):1323-33. PubMed ID: 16099044
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.